Advancements in Pharmacological Interventions and Novel Therapeutic Approaches for Amyotrophic Lateral Sclerosis
- PMID: 39457513
- PMCID: PMC11505100
- DOI: 10.3390/biomedicines12102200
Advancements in Pharmacological Interventions and Novel Therapeutic Approaches for Amyotrophic Lateral Sclerosis
Abstract
(1) Amyotrophic Lateral Sclerosis (ALS) is a neurodegenerative disease in which the patient suffers from an affection of both upper and lower motor neurons at the spinal and brainstem level, causing a progressive paralysis that leads to the patient's demise. Gender is also considered a predisposing risk factor for developing the disease. A brief review of the pathophysiological mechanisms of the disease is also described in this work. Despite the fact that a cure for ALS is currently unknown, there exists a variety of pharmacological and non-pharmacological therapies that can help reduce the progression of the disease over a certain period of time and alleviate symptoms. (2) We aim to analyze these pharmacological and non-pharmacological therapies through a systematic review. A comprehensive, multidisciplinary approach to treatment is necessary. (3) Drugs such as riluzole, edaravone, and sodium phenylbutyrate, among others, have been investigated. Additionally, it is important to stay updated on research on new drugs, such as masitinib, from which very good results have been obtained. (4) Therapies aimed at psychological support, speech and language, and physical therapy for the patient are also available, which increase the quality of life of the patients.
Keywords: ALS; amyotrophic lateral sclerosis; motor neuron dysfunction; multidisciplinary treatment; neurodegenerative disorder; pharmacological interventions.
Conflict of interest statement
The authors declare no conflicts of interest.
Figures
Similar articles
-
Exploring Advancements in the Treatment of Amyotrophic Lateral Sclerosis: A Comprehensive Review of Current Modalities and Future Prospects.Cureus. 2023 Sep 18;15(9):e45489. doi: 10.7759/cureus.45489. eCollection 2023 Sep. Cureus. 2023. PMID: 37868386 Free PMC article. Review.
-
Masitinib: The promising actor in the next season of the Amyotrophic Lateral Sclerosis treatment series.Biomed Pharmacother. 2023 Apr;160:114378. doi: 10.1016/j.biopha.2023.114378. Epub 2023 Feb 10. Biomed Pharmacother. 2023. PMID: 36774721 Review.
-
Impact of Plant-Derived Compounds on Amyotrophic Lateral Sclerosis.Neurotox Res. 2023 Jun;41(3):288-309. doi: 10.1007/s12640-022-00632-1. Epub 2023 Feb 17. Neurotox Res. 2023. PMID: 36800114 Review.
-
A perspective on therapies for amyotrophic lateral sclerosis: can disease progression be curbed?Transl Neurodegener. 2021 Aug 10;10(1):29. doi: 10.1186/s40035-021-00250-5. Transl Neurodegener. 2021. PMID: 34372914 Free PMC article. Review.
-
Cell-based therapies for amyotrophic lateral sclerosis/motor neuron disease.Cochrane Database Syst Rev. 2019 Dec 19;12(12):CD011742. doi: 10.1002/14651858.CD011742.pub3. Cochrane Database Syst Rev. 2019. PMID: 31853962 Free PMC article.
Cited by
-
Global, regional, and national epidemiology of neurological disorders and subcategories: incidence and disability-adjusted life years, 1990-2021.Eur J Med Res. 2025 Aug 5;30(1):711. doi: 10.1186/s40001-025-02958-w. Eur J Med Res. 2025. PMID: 40765055 Free PMC article.
References
-
- Hulisz D. Amyotrophic lateral sclerosis: Disease state overview. Am. J. Manag. Care. 2018;24:S320–S326. - PubMed
Publication types
Grants and funding
LinkOut - more resources
Full Text Sources
Miscellaneous